Advanced Medical Isotope Corporation Launches IsoPet Solutions to Focus on the Veterinary Market

KENNEWICK, WA / ACCESSWIRE / March 15, 2016 / Advanced Medical Isotope Corporation (or “AMI”) (OTC: ADMD), (www.IsotopeWorld.com) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market.

The IsoPet Solutions division will focus on bringing AMI’s yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers. There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. AMI expects the initial treatments to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.

AMI Founder, CEO and Chairman James C. Katzaroff stated: “Launching IsoPet Solutions allows specific resources to focus on the use of our yttrium-90 brachytherapy products in the veterinary space. We believe that AMI is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”

AMI Veterinary Medicine Advisory Board Chair Dr. Alice Stated: “I am thrilled to see the dedication of AMI to enter the veterinary markets through IsoPet Solutions. I am excited to work closely with the Company to launch its products for use in companion animals. In fact, our Pawspice practices are eager to make the treatments available as soon as possible, and we are preparing to offer treatments this spring.”

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.

CONTACTS:

Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336
509-736-4000

Investor Relations
Tyler M. Troup, B.Comm
Circadian Group IR, Managing Director
info@Circadian-Group.com
866-950-8300

SOURCE: Advanced Medical Isotope Corporation

ReleaseID: 437857